With Strong Safety Data For LibiGel, BioSante Raises $11.1 Million
This article was originally published in The Pink Sheet Daily
Down to about $6 million at the end of the second quarter, the sexual health products firm uses a merger and private placement to significantly upgrade its cash position.
You may also be interested in...
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.